Bio med central

HIGHLIGHTS

• who: Practice, and BioMed, Central from the Netherlands Cancer Institute, Amsterdam, The Netherlands, Department of Clinical Genetics and Human Genetics, VU University Medical have published the research: Bio Med Central, in the Journal: (JOURNAL) of 13,/Nov/2008
• what: The authors propose that the germline CHEK2 sequence variants contribute to tumour development in the index patients.
• how: The data are in line with the hypothesis that the CHEK2 c.1100delC might be associated with an elevated breast cancer risk and possibly with a breast and colorectal cancer phenotype or more generally a multi . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.